SciVac has filed an application with the FDA for approval to distribute its hepatitis B vaccine Sci-B-Vac to dialysis and HIV-positive patients. The Israeli firm plans to conduct a clinical trial in the U.S. and submit a similar application in Europe if it gets the FDA's nod. The vaccine "looks the same as the virus itself. The immune system cannot ignore it, so it gives full protection," CEO Michal Ben-Attar said.
Published in Brief: